| Author | Sonoi, Norihiro| Soga, Yoshihiko| Maeda, Hiroshi| Ichimura, Koichi| Yoshino, Tadashi| Aoyama, Kazutoshi| Fujii, Nobuharu| Maeda, Yoshinobu| Tanimoto, Mitsune| Logan, Richard| Raber-Durlacher, Judith| Takashiba, Shogo| |
|---|---|
| Published Date | 2012-07 |
| Publication Title | Odontology |
| Volume | volume100 |
| Issue | issue2 |
| Content Type | Journal Article |
| Title Alternative | Molecular targeted therapy in myeloma and lymphoma |
|---|---|
| FullText URL | 126_143.pdf |
| Author | Saeki, Kyosuke| Maeda, Yoshinobu| Tanimoto, Mitsune| |
| Keywords | 骨髄腫 リンパ腫 分子標的治療薬 |
| Publication Title | 岡山医学会雑誌 |
| Published Date | 2014-08-01 |
| Volume | volume126 |
| Issue | issue2 |
| Start Page | 143 |
| End Page | 150 |
| ISSN | 0030-1558 |
| language | Japanese |
| Copyright Holders | Copyright (c) 2014 岡山医学会 |
| File Version | publisher |
| DOI | 10.4044/joma.126.143 |
| NAID | 130004685266 |
| Title Alternative | Molecular targeted therapies in leukemia |
|---|---|
| FullText URL | 126_49.pdf |
| Author | Maeda, Yoshinobu| Tanimoto, Mitsune| |
| Keywords | 白血病 分子標的薬 チロシンキナーゼ阻害薬 |
| Publication Title | 岡山医学会雑誌 |
| Published Date | 2014-04-01 |
| Volume | volume126 |
| Issue | issue1 |
| Start Page | 49 |
| End Page | 54 |
| ISSN | 0030-1558 |
| Related Url | http://www.okayama-u.ac.jp/user/oma/ |
| language | Japanese |
| Copyright Holders | Copyright (c) 2014 岡山医学会 |
| File Version | publisher |
| DOI | 10.4044/joma.126.49 |
| Author | 杉浦 裕子| 曽我 賢彦| 前田 嘉信| |
|---|---|
| Published Date | 2010-09-01 |
| Publication Title | 造血細胞移植now&future |
| Volume | volume20 |
| Content Type | Article |
| Author | Hayashi, Eiko| Takata, Katsuyoshi| Sato, Yasuharu| Tashiro, Yukie| Tachiyama, Yoshiro| Sawada-Kitamura, Seiko| Hiramatsu, Yasushi| Sugiguchi, Shun| Nose, Soichiro| Hirokawa, Mitsuyoshi| Ando, Midori| Abd Mader, Lamia| Maeda, Yoshinobu| Tanimoto, Mitsune| Yoshino, Tadashi| |
|---|---|
| Published Date | 2013-09 |
| Publication Title | Human Pathology |
| Volume | volume44 |
| Issue | issue9 |
| Content Type | Journal Article |
| Author | Takata, Katsuyoshi| Sato, Yasuharu| Nakamura, Naoya| Tokunaka, Mami| Miki, Yukari| Kikuti, Yara Yukie| Igarashi, Kazuhiko| Ito, Etsuro| Harigae, Hideo| Kato, Seiichi| Hayashi, Eiko| Oka, Takashi| Hoshii, Yoshinobu| Tari, Akira| Okada, Hiroyuki| Mohamado, ABD Alkader Lamia| Maeda, Yoshinobu| Tanimoto, Mitsune| Kinoshita, Tomohiro| Yoshino, Tadashi| |
|---|---|
| Published Date | 2013-08-01 |
| Publication Title | 岡山医学会雑誌 |
| Volume | volume125 |
| Issue | issue2 |
| Content Type | Journal Article |
| Author | Soga, Yoshihiko| Maeda, Yoshinobu| Ishimaru, Fumihiko| Tanimoto, Mitsune| Maeda, Hiroshi| Nishimura, Fusanori| Takashiba, Shogo| |
|---|---|
| Published Date | 2011-07 |
| Publication Title | Supportive Care in Cancer |
| Volume | volume19 |
| Issue | issue7 |
| Content Type | Journal Article |
| Author | Takahashi, Kanayo| Soga, Yoshihiko| Murayama, Yumeno| Udagawa, Mika| Nishimoto, Hitomi| Sugiura, Yuko| Maeda, Yoshinobu| Tanimoto, Mitsune| Takashiba, Shogo| |
|---|---|
| Published Date | 2010-01 |
| Publication Title | Supportive Care in Cancer |
| Volume | volume18 |
| Issue | issue1 |
| Content Type | Journal Article |
| Author | Soga, Yoshihiko| Yamasuji, Yoshiko| Kudo, Chieko| Matsuura-Yoshimoto, Kaori| Yamabe, Kokoro| Sugiura, Yuko| Maeda, Yoshinobu| Ishimaru, Fumihiko| Tanimoto, Mitsune| Nishimura, Fusanori| Takashiba, Shogo| |
|---|---|
| Published Date | 2009-05 |
| Publication Title | Supportive Care in Cancer |
| Volume | volume17 |
| Issue | issue5 |
| Content Type | Journal Article |
| Author | Soga, Yoshihiko| Sugiura, Yuko| Takahashi, Kanayo| Nishimoto, Hitomi| Maeda, Yoshinobu| Tanimoto, Mitsune| Takashiba, Shogo| |
|---|---|
| Published Date | 2011-02 |
| Publication Title | Supportive Care in Cancer |
| Volume | volume19 |
| Issue | issue2 |
| Content Type | Journal Article |
| Author | Nishimori, Hisakazu| Maeda, Yoshinobu| Tanimoto, Mitsune| |
|---|---|
| Published Date | 2012-12-03 |
| Publication Title | 岡山医学会雑誌 |
| Volume | volume124 |
| Issue | issue3 |
| Content Type | Journal Article |
| Author | Asakura, Shoji| Hashimoto, Daigo| Takashima, Shuichiro| Sugiyama, Haruko| Maeda, Yoshinobu| Akashi, Koichi| Tanimoto, Mitsune| Teshima, Takanori| |
|---|---|
| Published Date | 2012-04-01 |
| Publication Title | 岡山医学会雑誌 |
| Volume | volume124 |
| Issue | issue1 |
| Content Type | Journal Article |
| Author | Itou Nao| Maeda Yoshinobu| Hayashi Toyohiko| |
|---|---|
| Published Date | 2009-11-11 |
| Publication Title | Proceedings : Fifth International Workshop on Computational Intelligence & Applications |
| Volume | volume2009 |
| Issue | issue1 |
| Content Type | Conference Paper |
| Author | 前田 嘉信| |
|---|---|
| Published Date | 1999-06-30 |
| Publication Title | |
| Content Type | Thesis or Dissertation |
| JaLCDOI | 10.18926/AMO/61904 |
|---|---|
| FullText URL | 75_2_219.pdf |
| Author | Sugiura, Hiroyuki| Nishimori, Hisakazu| Matsuoka, Hirofumi| Nakamura, Keiichiro| Fujii, Keiko| Fujii, Nobuharu | Matsuoka, Ken-ichi | Maeda, Yoshinobu| |
| Abstract | Acute promyelocytic leukemia (APL) is a hematological emergency that requires urgent intervention because of the high incidence of early hemorrhagic death. When patients with APL experience a synchronous solid organ tumor, the tumor’s treatment must also be done properly. Differentiation-inducing therapy using arsenic trioxide (ATO) has less hematological toxicity compared to cytotoxic chemotherapy and might be preferable for untreated APL patients with a synchronous solid organ tumor. Here we describe the first successful case of untreated APL and synchronous endometrial cancer (in an adult Japanese woman) treated with ATO consolidation therapy and the subsequent surgery and chemotherapy for endometrial cancer. |
| Keywords | acute promyelocytic leukemia endometrial cancer arsenic trioxide synchronous multiple primary malignant tumor chemotherapy |
| Amo Type | Case Report |
| Publication Title | Acta Medica Okayama |
| Published Date | 2021-04 |
| Volume | volume75 |
| Issue | issue2 |
| Publisher | Okayama University Medical School |
| Start Page | 219 |
| End Page | 224 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2021 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 33953429 |
| NAID | 120007029883 |
| JaLCDOI | 10.18926/AMO/61429 |
|---|---|
| FullText URL | 75_1_15.pdf |
| Author | Katsui, Kuniaki| Ogata, Takeshi| Tada, Akihiro| Sugiyama, Soichi| Yoshio, Kotaro| Kuroda, Masahiro| Kiura, Katsuyuki| Maeda, Yoshinobu| Toyooka, Shinichi| Hiraki, Takao| Kanazawa, Susumu| |
| Abstract | The aim of this study was to investigate whether volumetric positron emission tomography (PET) parameters are prognostic predictors in stage III non-small cell lung cancer patients receiving definitive concurrent chemo-radiotherapy (CCRT) with cisplatin/docetaxel. Cases involving definitive CCRT were reviewed retrospectively, and the maximum standardized uptake value, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated. The relationships between these PET parameters and prognosis were analyzed. MTV and TLG were significant predictors of distant metastasis-free survival (DMFS) (p = 0.0003 and 0.0005, respectively) and progression-free survival (PFS) (p = 0.001 and 0.0007, respectively). The three-year DMFS rates in patients with low and high MTV were 13.3% and 64.6%, respectively, and the corresponding values in those with low and high TLG were 13.3% and 65.2%, respectively. The three-year PFS rates in patients with low and high MTV were 13.3% and 57.8%, respectively, and the corresponding values in patients with low and high TLG were 13.3% and 57.8%, respectively. However, MTV and TLG were not predictors of local control or overall sur-vival. We demonstrated that volumetric PET parameters were predictors of patients receiving definitive CCRT. Our findings contradict the findings of previous reports and warrant further research to validate them. |
| Keywords | volumetric positron emission tomography parameters distant metastasis-free survival chemoradiotherapy cisplatin/docetaxel non-small cell lung cancer |
| Amo Type | Original Article |
| Publication Title | Acta Medica Okayama |
| Published Date | 2021-02 |
| Volume | volume75 |
| Issue | issue1 |
| Publisher | Okayama University Medical School |
| Start Page | 15 |
| End Page | 23 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2021 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 33649609 |
| JaLCDOI | 10.18926/AMO/60802 |
|---|---|
| FullText URL | 74_5_423.pdf |
| Author | Hirabae, Atsuko| Ichihara, Eiki| Sunami, Ryota| Ota, Moeko| Iwamoto, Yoshitaka| Maeda, Yoshinobu| Kiura, Katsuyuki| |
| Abstract | We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks. |
| Keywords | lung cancer immune checkpoint inhibitors pembrolizumab hyperprogression |
| Amo Type | Case Report |
| Publication Title | Acta Medica Okayama |
| Published Date | 2020-10 |
| Volume | volume74 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 423 |
| End Page | 425 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2020 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 33106698 |
| Web of Science KeyUT | 000581970100007 |
| NAID | 120006892928 |
| JaLCDOI | 10.18926/AMO/60796 |
|---|---|
| FullText URL | 74_5_371.pdf |
| Author | Makimoto, Go| Ohashi, Kadoaki| Maeda, Yoshinobu| Kiura, Katsuyuki| |
| Abstract | The prognosis of advanced non-small cell lung cancer (NSCLC) patients has improved in recent decades, especially for patients with an oncogenic driver mutation. Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are effective for patients with the echinoderm microtubule-associated protein-like 4-ALK fusion gene. Several ALK-TKIs have been established: the first-generation ALK-TKI, crizotinib; second-generation ALK-TKIs, alectinib and ceritinib; and third-generation ALK-TKI, lorlatinib. Some ALK-TKIs are effective for tumors that are resistant to other ALK-TKIs; however, as is known in epidermal growth factor receptormutant lung cancer, tumor resistance is inevitable. ALK-positive NSCLCs acquire resistance via various mechanisms, making it a heterogeneous disease. Therefore, it is necessary to develop next-generation treatment strategies, such as the use of next-generation ALK-TKIs for secondary mutations, or combination therapies with ALK-TKIs and other TKIs. In this review, we summarize the development and use of ALK-TKIs, prior pivotal clinical trials, and resistance mechanisms. |
| Keywords | lung cancer anaplastic lymphoma kinase tyrosine kinase inhibitors resistance mechanism |
| Amo Type | Review |
| Publication Title | Acta Medica Okayama |
| Published Date | 2020-10 |
| Volume | volume74 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 371 |
| End Page | 379 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2020 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 33106692 |
| Web of Science KeyUT | 000581970100001 |
| NAID | 120006892922 |
| JaLCDOI | 10.18926/AMO/54603 |
|---|---|
| FullText URL | 70_5_409.pdf |
| Author | Maeda, Yoshinobu| Nishimori, Hisakazu| Inamoto, Yoshihiro| Nakamae, Hirohisa| Sawa, Masashi| Mori, Yasuo| Ohashi, Kazuteru| Fujiwara, Shin-ichiro| Tanimoto, Mitsune| |
| Abstract | Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD. |
| Keywords | Am80 tamibarotene retinoid chronic GVHD steroid-refractory GVHD |
| Amo Type | Clinical Study Protocols |
| Publication Title | Acta Medica Okayama |
| Published Date | 2016-10 |
| Volume | volume70 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 409 |
| End Page | 412 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27777437 |
| Web of Science KeyUT | 000388098700014 |
| JaLCDOI | 10.18926/AMO/51868 |
|---|---|
| FullText URL | 67_5_319.pdf |
| Author | Murakawa, Kiminaka| Sato, Tomoaki| Maeda, Yoshinobu| Kitamura, Yoshihisa| Tanimoto, Mitsune| Sendo, Toshiaki| |
| Abstract | Graft-versus-host disease (GVHD) is a major concern in transplantation patients. Gut GVHD is accompanied by diarrhea, abdominal pain, and/or melena. Although oral treatment with corticosteroids (CSs) is effective in treating gut GVHD, it can cause adverse reactions that affect the entire body. Topical administration of CSs can be effective in treating diseases in which lesions are limited locally, because adverse reactions can then be alleviated. In this study, we examine and discuss an enteric-coated beclomethasone dipropionate (BDP) capsule (BDP-EC) formulated at Okayama University Hospital. The BDP-EC did not dissolve in solution 1 (pH1.2), and began disintegrating in solution 2 (pH6.8) after 5min, with a mean dissolution rate at 15min of 85%. We then used the capsule to treat a patient who developed gut GVHD after allogeneic hematopoietic stem cell transplantation. Clinically, the frequency of diarrhea decreased after BDP-EC administration. In addition, we were able to decrease the prednisolone equivalent dose. Symptoms associated with adverse reactions to BDP were not observed during the hospitalization period. These findings suggest that the administration of BDP-EC in the early stages of gut GVHD may allow a reduction in the initial doses of systemic CSs. |
| Keywords | beclomethasone intestinal graft-versus-host disease enteric-coated capsule in-hospital formulation |
| Amo Type | Case Report |
| Publication Title | Acta Medica Okayama |
| Published Date | 2013-10 |
| Volume | volume67 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 319 |
| End Page | 324 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2013 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 24145732 |
| Web of Science KeyUT | 000325836100006 |
